Presentation (CTI)

OBJECTIVES: Pharmaceutical industry partners increasingly support population-based screening initiatives, particularly in resource-constrained settings. Industry engagement can accelerate innovation in diagnostics, data generation, and early detection technologies, while governments retain responsibility for equitable implementation, financial protection, and continuity of care under universal health coverage (UHC). Patient-centricity—operationalized through meaningful patient advocacy group (PAG) involvement—is critical to ensuring that screening translates into real-world benefit. In many low- and middle-income country settings, misalignment between industry, patient, and government timelines can delay implementation. This study examines how public-private partnerships (PPPs) in population screening can align innovation, government implementation capacity, patient voice, institutional timelines, continuity safeguards, and transparency mechanisms, while avoiding the framing of screening as market access or demand generation.
METHODS: We conducted a policy and systems analysis of industry-supported population screening initiatives in low- and middle-income country contexts, synthesizing policy documents and stakeholder guidance. A conceptual framework mapped screening inputs to downstream access, equity, and health system outcomes, informed by HEOR principles, international screening governance standards, patient-centered design, and public-sector planning cycles.
RESULTS: Effective PPPs demonstrate complementarity between industry innovation capacity, government implementation authority, structured PAG involvement, synchronized stakeholder timelines, and explicit continuity safeguards. Programs incorporating defined referral pathways; linkage to financing and benefit packages; equity safeguards; early PAG engagement across planning and monitoring; alignment with legislative and budgetary rhythms; time-limited donor financing during gridlock or power vacuums; and shared dashboards tracking deliverables and resources are more likely to translate diagnostic yield into effective coverage and outcomes. Initiatives lacking such integration risk diagnosed but untreated populations and widening access gaps.
CONCLUSIONS: Public-private collaboration in population screening is essential for advancing UHC where innovation costs exceed public capacity. Pairing industry-led innovation with government-led implementation expertise, sustained PAG involvement, synchronized institutional timelines, continuity-focused governance, and transparent monitoring enables screening initiatives to move beyond demand signaling toward durable, equitable value creation.